Shukra Pharma Board Approves Shareholder Approval for Warrant Issue

Shukra Pharmaceuticals Ltd's Board of Directors met on June 10, 2026, to approve seeking fresh shareholder approval for a preferential issue of 46,43,000 Convertible Equity Warrants. The original approval from November 1, 2025, lapsed due to timing issues. The issue price will be re-computed as per SEBI ICDR Regulations, not lower than ₹34 per warrant. The company will hold an EGM on July 6, 2026, to pass a special resolution. Ms. Rupal Patel has been appointed as Scrutinizer. The total issue size is approximately ₹16.51 crore at a revised price of ₹35.56 per warrant.